Supplied ready in solution
Bone, Muscle & Other
At a glance
Ten answers, each one line. Open any row for the detail behind it.
What it does One of only a handful of drugs that build new bone rather than slowing its loss.
One of only a handful of drugs that build new bone rather than slowing its loss. Abaloparatide is close kin to teriparatide, and the honest summary of the difference is that the head-to-head data show comparable spine benefit, a possible edge at non-vertebral sites, and less hypercalcaemia — but the trial that would settle it on fracture outcomes alone has not been run.
Half-life Approximately 1 hour — Documented
Approximately 1 hour
Typical studied dose Set on the approved label, which states the starting dose, how it is… — On the label
Set on the approved label, which states the starting dose, how it is increased and the maximum. Read it there rather than anywhere else — including here.
How often it is used The label schedule is daily. Dosing intervals follow the half-life above… — On the label
The label schedule is daily. Dosing intervals follow the half-life above, and the prescribing information is what sets them.
How it is taken Subcutaneous injection daily; a transdermal patch is in development — Documented
Subcutaneous injection daily; a transdermal patch is in development
Main side effects Bone loss on stopping without follow-on therapy · Osteosarcoma signal in rats · Orthostatic hypotension — Carries serious risk
Bone loss on stopping without follow-on therapy — The single most consequential practical risk. Finishing the course and stopping treatment altogether gives much of the gain back. A follow-on antiresorptive is not optional.
Osteosarcoma signal in rats — Rats given high lifetime doses developed osteosarcoma. Human post-marketing surveillance has not reproduced it, and the boxed warning was withdrawn in 2021, but the rodent finding is the reason for prior cumulative-lifetime limits.
Orthostatic hypotension — Occurs in the first few hours after dosing, most often after the first doses. Injecting where the patient can sit or lie down is a standard precaution.
Storage before mixing Supplied already in solution and kept refrigerated, not frozen. Freezing…
Supplied already in solution and kept refrigerated, not frozen. Freezing a protein solution can aggregate it, which is not always visible.
Shelf life after mixing Nothing to mix — it is not supplied as a powder. The relevant date is…
Nothing to mix — it is not supplied as a powder. The relevant date is the one printed on the product.
Evidence level 5/5 · Very strong — Documented
Multiple phase 3 randomized trials plus regulatory approval in a major market.
Regulatory status FDA Approved — Documented
FDA-approved 2017 for postmenopausal osteoporosis at high fracture risk, extended in 2021 to men. The boxed warning for osteosarcoma was removed in 2021 after post-marketing surveillance failed to find the signal seen in rats. Prescription-only. Approved in the US, the EU and elsewhere; ordinarily reserved for high fracture risk after other therapy, both by guideline and by payer policy.
Overview
One of only a handful of drugs that build new bone rather than slowing its loss. Abaloparatide is close kin to teriparatide, and the honest summary of the difference is that the head-to-head data show comparable spine benefit, a possible edge at non-vertebral sites, and less hypercalcaemia — but the trial that would settle it on fracture outcomes alone has not been run.
FDA ApprovedFDA-approved 2017 for postmenopausal osteoporosis at high fracture risk, extended in 2021 to men. The boxed warning for osteosarcoma was removed in 2021 after post-marketing surveillance failed to find the signal seen in rats.
| Regulatory status | FDA-approved 2017 for postmenopausal osteoporosis at high fracture risk, extended in 2021 to men. The boxed warning for osteosarcoma was removed in 2021 after post-marketing surveillance failed to find the signal seen in rats. |
|---|---|
| Drug class | Synthetic 34-residue analogue of human parathyroid hormone-related protein PTHrP(1-34), with substitutions that bias it toward the RG conformation of the PTH1 receptor |
| Route | Subcutaneous injection daily; a transdermal patch is in development |
| Half-life | Approximately 1 hour |
| Evidence rating |
5/5 Very strong
Evidence rating 5 out of 5: Very strong
Multiple phase 3 randomized trials plus regulatory approval in a major market. |
| Studied in | ACTIVE randomized 2,463 postmenopausal women and showed an 86% reduction in new vertebral fractures against placebo over 18 months, with significant reductions in non-vertebral fracture. ACTIVExtend followed with alendronate and preserved the gain. ATOM extended approval to men on bone-density endpoints rather than fractures. |
Abaloparatide sequence & structure
Abaloparatide is a 34-residue linear peptide with a C-terminal amide, carrying non-standard residues; molecular weight 3,961 Da.
[bracketed] = non-standard residue
Synthetic analog of hPTHrP(1-34) differing at eight positions (Phe22→Glu, Phe23→Leu, His25→Glu, His26→Lys, Ile28→Leu, Ala29→Aib, Glu30→Lys, Ile31→Leu) plus a C-terminal amide; 76% identity to hPTHrP(1-34) and 41% to hPTH(1-34). The label/PubChem MW of 3961 Da is a rounded average mass (KEGG 3960.59; calculated from the formula 3960.66); Tymlos is formulated as the free peptide in acetate buffer, and the UniProt accession refers to the endogenous PTHrP precursor, not the drug itself.
Record confidence: high — two independent authoritative sources agree on the sequence and modifications. Every sequence on the site is listed with its sources on the peptide sequences index.
How it works
Selectively activates the PTH1 receptor with a preference for the transient RG conformation over the prolonged R0 state that teriparatide favours. The shorter signal is thought to favour osteoblast-driven bone formation over the osteoclast-driven resorption that follows sustained PTH1R signalling — the mechanistic basis for the reduced hypercalcaemia seen in trials.
Evidence base
Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.
- Fracture-outcome evidence in postmenopausal women is strong. The male approval rests on bone density, which is a surrogate.
- Abaloparatide has never been compared with teriparatide in a trial powered on fractures, so claims that one is superior go beyond the data.
- The 2021 removal of the boxed warning followed surveillance rather than a new trial — reassuring, but that is the strength of evidence it carries.
Benefits and risks, weighed against the evidence
Every entry below carries the strength of the evidence behind it — three bars for strong human data, two for moderate, one for preliminary or preclinical work. The two columns are not equal by design: where a compound has more documented risk than demonstrated benefit, the lists say so.
Reported benefits
5 entries · 4 on strong human evidence
-
Large reduction in vertebral fracture
An 86% relative reduction against placebo in ACTIVE, one of the largest anti-fracture effects recorded for any osteoporosis drug.
Evidence: Strong evidence -
Reduces non-vertebral fracture
A significant 43% reduction against placebo. This matters because non-vertebral fractures, particularly hip, drive most of the mortality.
Evidence: Strong evidence -
Anabolic rather than antiresorptive
Builds bone mass instead of slowing its loss, which is the reason it is reserved for patients who fracture despite bisphosphonates.
Evidence: Strong evidence -
Less hypercalcaemia than teriparatide
Roughly 3.4% versus 6.4% in the head-to-head arm of ACTIVE, consistent with the shorter receptor signal.
Evidence: Moderate evidence -
Gains are preserved by sequencing to an antiresorptive
Bone built during the anabolic course is lost within a year or two if nothing follows it. ACTIVExtend showed alendronate holds it.
Evidence: Strong evidence
Risks and cautions
5 entries · 1 serious or common
-
Bone loss on stopping without follow-on therapy
The single most consequential practical risk. Finishing the course and stopping treatment altogether gives much of the gain back. A follow-on antiresorptive is not optional.
Evidence: Serious -
Osteosarcoma signal in rats
Rats given high lifetime doses developed osteosarcoma. Human post-marketing surveillance has not reproduced it, and the boxed warning was withdrawn in 2021, but the rodent finding is the reason for prior cumulative-lifetime limits.
Evidence: Moderate evidence -
Orthostatic hypotension
Occurs in the first few hours after dosing, most often after the first doses. Injecting where the patient can sit or lie down is a standard precaution.
Evidence: Moderate evidence -
Hypercalcaemia and hypercalciuria
Less than with teriparatide but still present, and a reason to avoid it in anyone with pre-existing hypercalcaemia.
Evidence: Moderate evidence -
Palpitations and tachycardia
Reported more often than with teriparatide, generally transient.
Evidence: Minor
Counts are not a score. A single serious risk can outweigh several well-supported benefits, and a long benefit list built on preclinical work outweighs nothing at all.
Opinion — what people actually report
5 themes · 2 reported benefits · 2 reported problems
This is the weakest tier on this site. These are themes drawn from public discussion — forums, subreddits and patient threads — not from trials. There is no control group, no denominator, and no way to confirm that what someone injected matched its label. People post when a result is dramatic and when something goes wrong, and rarely when nothing happens, so treat everything below as a description of the conversation rather than of the compound. The bars count how often a thing is said, not how well it is supported.
-
Reported as easier than teriparatide Reported benefit. Recurring: Raised regularly, though not by everyone.
Patients who have used both often cite fewer calcium problems and a device they prefer, though such comparisons are inevitably informal.
-
Dizziness after the early doses Reported problem. Dominant theme: Comes up in most discussions of this compound.
The most distinctive complaint, and the reason the standing advice in patient groups is to inject somewhere you can sit down.
-
Cost and prior authorisation Reported problem. Dominant theme: Comes up in most discussions of this compound.
Dominates the discussion, as with all anabolic bone agents.
-
Scan results as motivation Reported benefit. Recurring: Raised regularly, though not by everyone.
Improving DXA numbers are reported as what makes daily injection sustainable.
-
Confusion about what happens after the course Practical note. Recurring: Raised regularly, though not by everyone.
Patients frequently report being unclear on why a follow-on drug is needed, or discovering it late.
Where the reports and the evidence part ways
The reported advantages over teriparatide — less hypercalcaemia, a preferred device — are consistent with trial data on calcium and with how the product is formulated, but no fracture-powered head-to-head trial has been run, so claims that one is better are informal comparison rather than established fact. The orthostatic hypotension patients describe is documented and dose-timing-related. The most important gap is again the sequencing one: the evidence that gains are lost without follow-on antiresorptive therapy is strong, and it is the thing patients most often report not having understood.
Readers on Abaloparatide
Questions and answers from readers, under generated names. Nothing here has been checked or reviewed by the site and none of it is medical advice. It is the least verified thing on this page — and it is here because people ask each other these things anyway, and most of the other places they can ask are run by sellers.
0 questions · 0 answers
No questions yet. Ask the first one above — it takes one box and an email address.
How names work, and the house rules
Names. Every verified address is given one generated name — two ordinary words — and keeps it. Nobody chooses a name and nobody can take another's. Posts marked desk were written by the site's own editorial desk, usually to open a thread; they carry a generated name like everyone else's and are held to the site's rules, which means they never state an amount.
What is not allowed. Selling, sourcing, vendor names, coupon codes and "message me" — posts that read that way are held and usually removed. Personal medical details you would not want public. Abuse. Instructions framed as what someone else should do.
What this is not. A reader's report of what happened to them is a report, not a finding, and an answer here is one person's view. Nothing in this section changes the evidence rating above it. If something you read here would change what you take, take it to a pharmacist or physician first.
Your data. Delete any post of yours at any time, or remove everything you have written together with your name. Details in the privacy notice.
Who should avoid it
- Pre-existing hypercalcaemia or primary hyperparathyroidism
- Prior skeletal radiation therapy
- Paget's disease or unexplained raised alkaline phosphatase
- Bone metastases or a history of skeletal malignancy
- Pregnancy and breastfeeding
If used under medical supervision, monitor
- Serum calcium before starting and periodically
- Uric acid, which rises in a minority
- DXA at 12–24 months
- Blood pressure sitting and standing after early doses
- An explicit plan for the antiresorptive that follows
Regulatory & legal status
Prescription-only. Approved in the US, the EU and elsewhere; ordinarily reserved for high fracture risk after other therapy, both by guideline and by payer policy.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Abaloparatide
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
- DailyMed — official FDA prescribing information
Related peptides in Bone, Muscle & Other
Terms used on this page
- Bone Remodelling
- Bone remodelling is the lifelong coupled cycle in which osteoclasts resorb a packet of bone and osteoblasts refill it, continuously renewing the skeleton without changing its shape.
- Menopause and Andropause
- Menopause is the permanent cessation of ovarian follicular function confirmed after twelve months of amenorrhoea, while andropause names a gradual and far less universal decline in male testosterone.
- Bone Mineral Density (BMD)
- Bone mineral density is the mineral content of bone per unit of projected area measured by DXA, expressed as grams per square centimetre and reported clinically as a T-score.
- Hierarchy of Evidence
- The hierarchy of evidence ranks study designs by how exposed they are to bias when answering a treatment question, from systematic reviews of randomised trials down to mechanistic reasoning and opinion.
- Boxed Warning
- A boxed warning is the strongest warning the FDA can place on a drug label, set in a box at the top of the prescribing information for risks of death or serious injury.
- Placebo and Placebo Control
- A placebo is an inactive intervention matched to the real one in appearance and route, used as a control arm so that improvement caused by the drug can be separated from improvement that would occur anyway.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.